Objective:

To investigate longitudinal changes in blood pressure associated with IL-17A inhibition in patients with axial spondyloarthritis (ax-SpA).

Approach:

Key Findings:

• IL-17A inhibition significantly improved disease activity and reduced inflammatory markers (p < 0.001).
• Systolic blood pressure (SBP) and diastolic blood pressure (DBP) showed time-dependent decreases.
• Estimated reductions were 0.90 mmHg for SBP and 0.91 mmHg for DBP every 4 weeks.
• Mean arterial pressure (MAP) also showed time-dependent decreases.
• Patients with baseline hypertension exhibited a more pronounced decline in DBP.
• After 12 weeks, SBP and DBP decreased by 4.80 mmHg and 5.10 mmHg, respectively.

Interpretation:

IL-17A inhibition is associated with effective control of disease activity and a reduction in blood pressure in ax-SpA patients, particularly in those with baseline hypertension.

Limitations:

• Uncontrolled study design necessitates confirmation in randomized trials.

Conclusion:

These findings provide preliminary clinical evidence regarding the relationship between IL-17A inhibition and blood pressure changes in patients with ax-SpA.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.